The role of circular RNA plasmacytoma variant translocation 1 as a biomarker for prognostication of acute myeloid leukemia

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Adult Acute Myeloid Leukemia Treatment (PDQ(R)): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD)2002.
   Google Scholar
• Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia Version 1 [database on the Internet]2021. Available from: https://www.nccn.org.
   Google Scholar
• Pollyea DA, Bixby D, Perl A, et al. NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16–27.
   PubMed Web of Science ®Google Scholar
• Morsink LM, Sandmaier BM, Othus M, et al. Conditioning intensity, pre-transplant flow cytometric measurable residual disease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Cancers (Basel). 2020;12(9):2339.
   Web of Science ®Google Scholar
• Tiribelli M, Michelutti A, Cavallin M, et al. Impact of concomitant aberrant CD200 and BCL2 overexpression on outcome of acute myeloid leukemia: a cohort study from a single center. Turk J Haematol. 2021;38(2):119–125.
   PubMed Web of Science ®Google Scholar
• Kamal AM, Nabih NA, Elleboudy NS, et al. Expression of immune check point gene TIM-3 in patients newly diagnosed with acute myeloid leukemia: significance and impact on outcome. Oncol Lett. 2021;21(4):325.
   PubMed Web of Science ®Google Scholar
• Izadifard M, Pashaiefar H, Yaghmaie M, et al. Expression analysis of PVT1, CCDC26, and CCAT1 long noncoding RNAs in acute myeloid leukemia patients. Genet Test Mol Biomarkers. 2018;22(10):593–598.
   PubMed Web of Science ®Google Scholar
• Ghadiri A, Sharifi M, Mehrzad V, et al. Reduce proliferation of human bone marrow cells from acute myeloblastic leukemia with minimally differentiation by blocking lncRNA PVT1. Clin Transl Oncol. 2020;22(11):2103–2110.
   PubMed Web of Science ®Google Scholar
• Cheng J, Song Y, Xu J, et al. LncRNA PVT1 promotes the malignant progression of acute myeloid leukaemia via sponging miR-29 family to increase WAVE1 expression. Pathology. 2021;53(5):613–622.
   PubMed Web of Science ®Google Scholar
• Hu J, Han Q, Gu Y, et al. Circular RNA PVT1 expression and its roles in acute lymphoblastic leukemia. Epigenomics. 2018;10(6):723–732.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia Version 2 [database on the Internet]2013. Available from: https://www.nccn.org.
   Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
   PubMed Web of Science ®Google Scholar
• Li M, Chi C, Zhou L, et al. Circular PVT1 regulates cell proliferation and invasion via miR-149-5p/FOXM1 axis in ovarian cancer. J Cancer. 2021;12(2):611–621.
   PubMed Web of Science ®Google Scholar
• Bian Q. Circular RNA PVT1 promotes the invasion and epithelial-mesenchymal transition of breast cancer cells through serving as a competing endogenous RNA for miR-204-5p. Onco Targets Ther. 2019;12:11817–11826.
   PubMed Web of Science ®Google Scholar
• Ghetti M, Vannini I, Storlazzi CT, et al. Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin. Mol Cancer. 2020;19(1):69.
   PubMed Web of Science ®Google Scholar
• Qin S, Zhao Y, Lim G, et al. Circular RNA PVT1 acts as a competing endogenous RNA for miR-497 in promoting non-small cell lung cancer progression. Biomed Pharmacother. 2019;111:244–250.
   PubMed Web of Science ®Google Scholar
• Mai S, Zhang Z, Mi W. Upregulation of circ_PVT1 and circ_001569 indicate unfavorable prognosis in colorectal cancer. Ann Clin Lab Sci. 2021;51(1):55–60.
   PubMed Web of Science ®Google Scholar
• Carramusa L, Contino F, Ferro A, et al. The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells. J Cell Physiol. 2007;213(2):511–518.
   PubMed Web of Science ®Google Scholar
• Abbate AL, Tolomeo D, Cifola I, et al. MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences. Leukemia. 2018;32(10):2152–2166.
   PubMed Web of Science ®Google Scholar
• Basit F, Andersson M, Hultquist A. The Myc/Max/Mxd network is a target of mutated Flt3 signaling in hematopoietic stem cells in Flt3-ITD-induced myeloproliferative disease. Stem Cells Int. 2018;2018:3286949.
   PubMed Web of Science ®Google Scholar
• Wu G, Suo C, Yang Y, et al. MYC promotes cancer progression by modulating m(6) a modifications to suppress target gene translation. EMBO Rep 2021;22(3):e51519.
   PubMed Web of Science ®Google Scholar
• Yan M, Gao H, Lv Z, et al. Circular RNA PVT1 promotes metastasis via regulating of miR-526b/FOXC2 signals in OS cells. J Cell Mol Med. 2020;24(10):5593–5604.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang Y, Li W, et al. Knockdown of cir_RNA PVT1 elevates gastric cancer cisplatin sensitivity via sponging miR-152-3p. J Surg Res. 2021;261:185–195.
   PubMed Web of Science ®Google Scholar
• Ebian HF, Elshorbagy S, Mohamed H, et al. Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: a single-center study. Cancer Biomark. 2021. DOI:https://doi.org/10.3233/CBM-210024
   Google Scholar